vimarsana.com

Latest Breaking News On - Erythropoiesis stimulating agent - Page 1 : vimarsana.com

ESA Treatment Selection in MDS

Clinical insights on selecting appropriate erythropoiesis-stimulating agents in patients with myelodysplastic syndromes.

Evolving treatment landscapeMyelodysplastic syndromesMds treatmentMyelodysplastic syndromes treatmentErythropoiesis stimulating agent

Erythropoietin Resistance Increases Risk of Mortality in Patients with Anemia, CKD

Patients on maintenance hemodialysis classified as having a high erythropoietin resistance index had a greater risk of all-cause mortality.

Li zuoAlebund li zuoNational institutes of healthUniversity people hospitalHealth libraryPeking university peopleChina dialysis outcomesPractice patterns studyChronic kidneyChronic kidney diseaseErythropoiesis stimulating agent

Efficacy and Safety of Luspatercept versus Epoetin Alfa in Erythropoiesis-Stimulating Agent-Naïve Patients with Transfusion-Dependent Lower-Risk Myelodysplastic Syndromes: Full Analysis of the COMMANDS Trial

Guillermo Garcia-Manero, MD, presents data from the COMMANDS trial investigating luspatercept in erythropoiesis-stimulating agent-naive patients with transfusion-dependent lower-risk myelodysplastic syndromes.

San diegoUnited statesGuillermo garcia maneroInternational prognostic scoring systemEpoetin alfaErythropoiesis stimulating agent naFull analysisPartnership withRevised international prognostic scoring systemCommands trialMyelodysplastic syndromesCommands studyCommands resultsCommands dataMash 2023Transfusion dependent lower risk mds

Bristol Myers Squibb s First Disclosures and New Data at ASH 2023 Highlight Company s Leadership and Progress in Cell Therapy, Targeted Protein Degradation and Novel Approaches in Hematology -November 02, 2023 at 11:35 am EDT

First presentation of results from primary analysis of Phase 2 TRANSCEND FL study evaluating second-line treatment with Breyanzi® in relapsed or refractory follicular lymphoma demonstrate its.

United statesSan diegoSikander ailawadhiFrancesco passamontiLisocabtagene maraleucelGuillaume cartronRavi vijMaroof hasanMark kaplanRachid bazHemophagocytic lymphohistiocytosisDanny jeyarajuSheida hayatiSusan balSamit hirawatFranck morschhauser

Clinical Management of Patients with Lower-risk MDS

Ralph Boccia, MD, FACP, highlights emerging therapies and the importance of next-generation sequencing for patients with MDS.

Ralph bocciaClinical managementMyelodysplastic syndromesFrontline therapyMds treatment managementAdverse eventsPre transfusion dependent patientErythropoiesis stimulating agentCombination therapy

vimarsana © 2020. All Rights Reserved.